Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 10/20 | 0.58 |
| ▸ | CDK2 | P24941 | 9/20 | 0.58 |
| ▸ | KMO | O15229 | 1/20 | 0.57 |
| ▸ | CDK5 | Q00535 | 6/20 | 0.54 |
| ▸ | CDK5R1 | Q15078 | 6/20 | 0.54 |
| ▸ | PRKACA | P17612 | 5/20 | 0.51 |
| ▸ | AURKA | O14965 | 2/20 | 0.51 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.51 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.51 |
| ▸ | GSK3B | P49841 | 5/20 | 0.51 |
| ▸ | CCNB2 | O95067 | 4/20 | 0.51 |
| ▸ | CCNB1 | P14635 | 4/20 | 0.51 |
| ▸ | PRKACG | P22612 | 4/20 | 0.51 |
| ▸ | PRKACB | P22694 | 4/20 | 0.51 |
| ▸ | CCNB3 | Q8WWL7 | 4/20 | 0.51 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.51 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.51 |
| ▸ | CSNK1E | P49674 | 2/20 | 0.51 |
| ▸ | CSNK1G2 | P78368 | 2/20 | 0.51 |
| ▸ | CSNK1G1 | Q9HCP0 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6641629 | 0.90 | CDK1 (0.50) | CDK1CDK2KMOCDK5CDK5R1 | |
| SCHEMBL6642591 | 0.90 | CDK1 (0.50) | CDK1CDK2KMOCDK5CDK5R1 | |
| SCHEMBL6638558 | 0.90 | KMO (0.50) | CDK1CDK2KMOCDK5CDK5R1 | |
| SCHEMBL6638621 | 0.89 | CDK1 (0.53) | CDK1CDK2KMOCDK5CDK5R1 | |
| SCHEMBL6637656 | 0.88 | CDK1 (0.52) | CDK1CDK2KMOCDK5CDK5R1 | |
| SCHEMBL6642317 | 0.88 | CDK2 (0.52) | CDK1CDK2KMOCDK5CDK5R1 | |
| SCHEMBL6638108 | 0.88 | CDK1 (0.52) | CDK1CDK2KMOCDK5CDK5R1 | |
| SCHEMBL6640518 | 0.87 | CDK1 (0.51) | CDK1CDK2KMOCDK5CDK5R1 | |
| SCHEMBL6643177 | 0.87 | KMO (0.55) | CDK1CDK2KMOCDK5CDK5R1 | |
| SCHEMBL7118368 | 0.86 | CDK1 (0.51) | CDK1CDK2KMOCDK5CDK5R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1412327-A2 | INHIBITORS OF PROTEIN KINASE FOR THE TREATMENT OF DISEASE | LG Biomedical Institute (US) | 2004-04-28 | — | — | EP | claimed |
| US-20030187007-A1 | Inhibitors of protein kinase for the treatment of disease | LG BIOMEDICAL INSTITUTE | 2003-10-02 | — | — | US | claimed |
| WO-2002096867-A2 | INHIBITORS OF PROTEIN KINASE FOR THE TREATMENT OF DISEASE | LG BIOMEDICAL INSTITUTE (US) | 2002-12-05 | — | — | WO | claimed |
| US-20260049282-A1 | METHOD FOR REMOVING SENESCENT CELL, AND METHOD FOR PREPARING SENESCENT CELL | THE UNIVERSITY OF TOKYO (JP) | 2026-02-19 | — | — | US | disclosed |
| CN-112996541-B | Method for removing senescent cells and method for producing senescent cells | 国立大学法人东京大学 | 2024-08-06 | — | — | CN | disclosed |
| US-20220119768-A1 | METHOD FOR REMOVING SENESCENT CELL, AND METHOD FOR PREPARING SENESCENT CELL | THE UNIVERSITY OF TOKYO (JP) | 2022-04-21 | — | — | US | disclosed |
| EP-3878470-A1 | METHOD FOR REMOVING SENESCENT CELL, AND METHOD FOR PREPARING SENESCENT CELL | The University of Tokyo (JP) | 2021-09-15 | — | — | EP | disclosed |
| CN-112996541-A | Method for removing senescent cells and method for preparing senescent cells | 国立大学法人东京大学 | 2021-06-18 | — | — | CN | disclosed |
| US-20200155521-A1 | PHARMACEUTICAL COMBINATION FOR TREATMENT OF CANCER | ARQULE, INC. | 2020-05-21 | — | — | US | disclosed |
| US-20200155521-A1 | PHARMACEUTICAL COMBINATION FOR TREATMENT OF CANCER | ARQULE, INC. | 2020-05-21 | — | — | US | disclosed |
| US-20030208067-A1 | Inhibitors of protein kinase for the treatment of disease | LG BIOMEDICAL INSTITUTE | 2003-11-06 | — | — | US | disclosed |
| US-20030187007-A1 | Inhibitors of protein kinase for the treatment of disease | LG BIOMEDICAL INSTITUTE | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200155521-A1 | PHARMACEUTICAL COMBINATION FOR TREATMENT OF CANCER | TP53, KRAS, VHL | CDK1 230/4885CDK2 170/4885KMO 3551/4885 |
| US-20030208067-A1 | Inhibitors of protein kinase for the treatment of disease | MAP3K20, MAP3K1, MAP3K2 | CDK1 82/4885CDK2 84/4885KMO 881/4885 |
| US-20030187007-A1 | Inhibitors of protein kinase for the treatment of disease | MAP3K20, MAP3K1, MAP3K2 | CDK1 82/4885CDK2 84/4885KMO 881/4885 |
| US-20260049282-A1 | METHOD FOR REMOVING SENESCENT CELL, AND METHOD FOR PREPARING SENESCENT CELL | GLS, PLK1, GLS2 | CDK1 27/4885CDK2 53/4885KMO 875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.